These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

998 related articles for article (PubMed ID: 16528136)

  • 1. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.
    Olié JP; Spina E; Murray S; Yang R
    Int Clin Psychopharmacol; 2006 May; 21(3):143-51. PubMed ID: 16528136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
    Ratner Y; Gibel A; Yorkov V; Ritsner MS
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1401-9. PubMed ID: 17669574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L; Meng X; Hochfeld M; Stahl SM
    Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia.
    Cutler AJ; Kalali AH; Weiden PJ; Hamilton J; Wolfgang CD
    J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S20-8. PubMed ID: 18334909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial.
    Addington DE; Pantelis C; Dineen M; Benattia I; Romano SJ
    J Clin Psychiatry; 2004 Dec; 65(12):1624-33. PubMed ID: 15641867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial.
    Berk M; Copolov D; Dean O; Lu K; Jeavons S; Schapkaitz I; Anderson-Hunt M; Judd F; Katz F; Katz P; Ording-Jespersen S; Little J; Conus P; Cuenod M; Do KQ; Bush AI
    Biol Psychiatry; 2008 Sep; 64(5):361-8. PubMed ID: 18436195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of ziprasidone in the treatment of first-episode psychosis: an 8-week, open-label, multicenter trial.
    Zhao T; Park TW; Yang JC; Huang GB; Kim MG; Lee KH; Chung YC
    Int Clin Psychopharmacol; 2012 Jul; 27(4):184-90. PubMed ID: 22426471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics].
    Bartkó G; Trixler M; Bitter I; Degrell I; Füredi J; Faludi G;
    Neuropsychopharmacol Hung; 2006 Dec; 8(4):201-9. PubMed ID: 17211055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial.
    Nakamura M; Ogasa M; Guarino J; Phillips D; Severs J; Cucchiaro J; Loebel A
    J Clin Psychiatry; 2009 Jun; 70(6):829-36. PubMed ID: 19497249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: a randomized, open-label, controlled trial.
    Kim SW; Shin IS; Kim JM; Lee SH; Lee JH; Yoon BH; Yang SJ; Hwang MY; Yoon JS
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1504-9. PubMed ID: 17692448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
    Gibel A; Ritsner MS
    Clin Neuropharmacol; 2008; 31(4):204-20. PubMed ID: 18670244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial.
    Zink M; Kuwilsky A; Krumm B; Dressing H
    J Psychopharmacol; 2009 May; 23(3):305-14. PubMed ID: 18562423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial.
    Stahl SM; Malla A; Newcomer JW; Potkin SG; Weiden PJ; Harvey PD; Loebel A; Watsky E; Siu CO; Romano S
    J Clin Psychopharmacol; 2010 Aug; 30(4):425-30. PubMed ID: 20571437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dosage finding and outcome in the treatment of schizophrenic inpatients with amisulpride. Results of a drug utilization observation study.
    Linden M; Scheel T; Xaver Eich F
    Hum Psychopharmacol; 2004 Mar; 19(2):111-9. PubMed ID: 14994321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement in antipsychotic-related metabolic disturbances in patients with schizophrenia switched to ziprasidone.
    Montes JM; Rodriguez JL; Balbo E; Sopelana P; Martin E; Soto JA; Delgado JF; Diez T; Villardaga I
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):383-8. PubMed ID: 17129654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amisulpride: a review of its efficacy in schizophrenia.
    Möller HJ
    Acta Psychiatr Scand Suppl; 2000; 400():17-22. PubMed ID: 10823307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of switching to ziprasidone in italian patients with acute exacerbation of schizophrenia: an open-label trial.
    Mencacci C;
    Pharmacopsychiatry; 2012 Sep; 45(6):236-40. PubMed ID: 22592506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
    Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
    Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study.
    Zimbroff D; Warrington L; Loebel A; Yang R; Siu C
    Int Clin Psychopharmacol; 2007 Nov; 22(6):363-70. PubMed ID: 17917555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.